Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Faeth Therapeutics, Inc. (FTH : NSDQ)

• Company Description    Faeth Therapeutics Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth Therapeutics Inc., formerly known as Sensei Biotherapeutics Inc., is based in AUSTIN, Texas. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $40.05 Daily Weekly Monthly 20 Day Moving Average: 286,060 shares Shares Outstanding: 25.84 (millions) Market Capitalization: $1,034.91 (millions) Beta: -0.28 52 Week High: $42.14 52 Week Low: $7.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 40.18% 40.81% 12 Week 189.17% 183.01% Year To Date 275.35% 232.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 701 TILLERY STREET #12 #1010 - AUSTIN,TX 20850 USA ph: 512-200-2982 fax: - ir@faeththerapeutics.com http://www.faeththerapeutics.com

• General Corporate Information    Officers Christopher W. Gerry - Chief Executive Officer; President and General Cou Josiah Craver - Senior Vice President of Finance Bob Holmen - Director Thomas Ricks - Director Kristian Humer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81728A207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 25.84 Most Recent Split Date: 6.00 (0.05:1) Beta: -0.28 Market Capitalization: $1,034.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-13.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.98 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 27.37% vs. Previous Quarter: 97.84% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -1,012.17 03/31/26 - - 12/31/25 - -83.59 ROA 06/30/26 - -175.69 03/31/26 - -256.50 12/31/25 - -69.97 Current Ratio 06/30/26 - 19.69 03/31/26 - 14.39 12/31/25 - 5.06 Quick Ratio 06/30/26 - 19.69 03/31/26 - 14.39 12/31/25 - 5.06 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 6.69 03/31/26 - -102.36 12/31/25 - 14.74 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - - 12/31/25 - 0.00

Powered by Zacks Investment Research ©